zipjet: I have a business question for you about Teva.
One reason Teva is so aggressive with at-risk generic-drug launches is that Teva has insurance for the possibility of an adverse legal ruling (and potentially the awarding of treble damages).
As a % of the at-risk sales, how much do you think Teva has to pay for this kind of insurance? T.i.a.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”